Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emraclidine - Cerevel Therapeutics

Next Previous
X
Search
Drug Profile

Emraclidine - Cerevel Therapeutics

Alternative Names: CVL-231; PF-06852231

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Antidementias; Antipsychotics; Azetidines; Fluorobenzenes; Ketones; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Muscarinic M4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • Phase I Alzheimer's disease

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in Belgium (PO)
  • 01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
  • 20 Jun 2024 Cerevel Therapeutics completes phase-I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT06366243)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top